期刊
BMJ CASE REPORTS
卷 14, 期 6, 页码 -出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/bcr-2021-243629
关键词
COVID-19; immunological products and vaccines; vaccination; immunisation; peripheral nerve disease
This case report presents a instance of Guillain-Barre syndrome occurring after receiving the Oxford/AstraZeneca COVID-19 vaccine. While a direct link could not be established, it emphasizes the need to consider this issue when evaluating cases of GBS.
Guillain-Barre syndrome (GBS) is a rare immune-mediated disorder of the peripheral nerves. Although its cause is not fully understood, the syndrome often follows infection with a virus or bacteria, although in rare occasions, vaccination may precede GBS. We describe a case of a 62-year-old woman who presented with paraesthesia and progressive weakness of both lower limbs over 3 days. Clinical examination and investigation findings including lumbar puncture and nerve conduction studies were consistent with the diagnosis of GBS. She had no history of either diarrhoea or respiratory tract infections preceding her presentation. However, she had her first intramuscular dose of the Oxford/AstraZeneca COVID-19 vaccine 11 days prior to her presentation. Although no direct link could be ascertained, the purpose of this report is to highlight the incidence and consider this issue while evaluating any case of GBS in the light of the current pandemic and vaccination programme.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据